Stanford University researchers have developed an innovative spray drying formulation platform enabling the conversion of traditionally intravenous protein therapeutics into stable, high-concentration injectable formulations suitable for autoinjector delivery. Incorporating a high-glass-transition temperature polymeric surfactant (MoNi), the method prevents protein aggregation and reduces viscosity challenges at elevated concentrations. Published in Science Translational Medicine, this technology could transform biologic drug administration by reducing reliance on lengthy IV infusions, enhancing patient convenience and lowering healthcare delivery costs.